Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 34
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Molecules ; 29(10)2024 May 09.
Artigo em Inglês | MEDLINE | ID: mdl-38792079

RESUMO

Infectious diseases caused by trypanosomatids, including African trypanosomiasis (sleeping sickness), Chagas disease, and different forms of leishmaniasis, are Neglected Tropical Diseases affecting millions of people worldwide, mainly in vulnerable territories of tropical and subtropical areas. In general, current treatments against these diseases are old-fashioned, showing adverse effects and loss of efficacy due to misuse or overuse, thus leading to the emergence of resistance. For these reasons, searching for new antitrypanosomatid drugs has become an urgent necessity, and different metabolic pathways have been studied as potential drug targets against these parasites. Considering that trypanosomatids possess a unique redox pathway based on the trypanothione molecule absent in the mammalian host, the key enzymes involved in trypanothione metabolism, trypanothione reductase and trypanothione synthetase, have been studied in detail as druggable targets. In this review, we summarize some of the recent findings on the molecules inhibiting these two essential enzymes for Trypanosoma and Leishmania viability.


Assuntos
Amida Sintases , Glutationa , NADH NADPH Oxirredutases , Trypanosoma , NADH NADPH Oxirredutases/metabolismo , NADH NADPH Oxirredutases/antagonistas & inibidores , Humanos , Amida Sintases/metabolismo , Amida Sintases/antagonistas & inibidores , Trypanosoma/efeitos dos fármacos , Trypanosoma/metabolismo , Glutationa/metabolismo , Glutationa/análogos & derivados , Animais , Espermidina/análogos & derivados , Espermidina/metabolismo , Leishmania/efeitos dos fármacos , Leishmania/metabolismo , Tripanossomicidas/farmacologia , Tripanossomicidas/uso terapêutico , Leishmaniose/tratamento farmacológico , Leishmaniose/metabolismo , Leishmaniose/parasitologia , Trypanosomatina/metabolismo , Trypanosomatina/efeitos dos fármacos , Proteínas de Protozoários/metabolismo , Proteínas de Protozoários/antagonistas & inibidores , Doença de Chagas/tratamento farmacológico , Doença de Chagas/parasitologia , Doença de Chagas/metabolismo
2.
Braz J Infect Dis ; 28(2): 103736, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38467387

RESUMO

Trypanosomatids are an important group of parasites that predominate in tropical and subtropical areas of the planet, which cause diseases that are classified as forgotten and neglected by the world health organization. In this group of parasites, we find Trypanosoma cruzi, Trypanosoma brucei, Trypanosoma brucei rhodesiense and Leishmania spp, for which there is no vaccine available, and its control has focused mainly on pharmacological treatment. Due to the poverty situation where these diseases are found and the biological complexity of these parasites, there are multiple variables to control, including the diversity of species, the complexity of their life cycles, drug resistance, cytotoxicity, the limited use in pregnant women, the high costs of treatment and the little-known pharmacological mechanisms of action, among others. It is therefore necessary to find new strategies and approaches for the treatment of these parasitic diseases. Among these new approaches is the rational search for new targets based on the allosteric inhibition of protein kinases, which have been little studied in trypanosomatids. Among these kinases, we find Glycogen Synthase Kinase-3 (GSK-3), a kinase of great pharmacological interest, which is under intense basic and clinical research by pharmaceutical companies for the treatment of cancer. This kinase, highly studied in the PI3K/AKT/mTOR pathway signaling in humans, has an orthologous gene in these parasites (GSK-3 s), which has proven to be essential for them in response to different challenges; Therefore, it is notable to increase research in this kinase in order to achieve a broad structural and functional characterization in the different species of trypanosomatids.


Assuntos
Quinase 3 da Glicogênio Sintase , Quinase 3 da Glicogênio Sintase/antagonistas & inibidores , Humanos , Animais , Trypanosomatina/enzimologia , Trypanosomatina/efeitos dos fármacos , Trypanosomatina/genética
3.
Bol. latinoam. Caribe plantas med. aromát ; 21(6): 737-756, nov. 2022. tab, graf, ilus
Artigo em Inglês | LILACS | ID: biblio-1554687

RESUMO

The objective of this study was to investigate the seasonal variance of the content and chemical composition of the essential oil from Lantana camara accessions at two harvest times, and to analyze the trypanocidal activity on Phytomonas serpens. Essential oil content ranged from 0.13 to 0.29% in the rainy season and from 0.13 to 0.33% in the dry season. The compounds E-caryophyllene, α-humulene, α-curcumene and germacrene D defined the formation of four chemical clusters in the rainy and dry seasons, classified as: Cluster 1 (E-caryophyllene + germacrene D); Cluster 2 (germacrene D + E-caryophyllene); Cluster 3 (α-humulene + E-caryophyllene); and Cluster 4 (α-curcumene + E-caryophyllene). All L. camara essential oils, representing the four chemical clusters, inhibited P. serpenswith low concentrations, considering the following IC50 values: 18.34±6.60 µg/mL (LAC-018, Cluster 1); 9.14±3.87 µg/mL (LAC-027, Cluster 2); 14.56±3.40 µg/mL (LAC-037, Cluster 3); and 14.97±2.68 µg/mL (LAC-019, Cluster 4).


El objetivo de este estudio fue investigar la variación estacional del contenido y la composición química del aceite esencial de accesiones de Lantana camara en dos tiempos de cosecha y analizar la actividad tripanocida en Phytomonas serpens. El contenido de aceite esencial osciló entre 0,13% y 0,29% en la temporada de lluvias y entre 0,13% y 0,33% en la temporada seca. Los compuestos E-cariofileno, α-humuleno, α-curcumeno y germacreno D definieron la formación de cuatro grupos químicos en las estaciones lluviosa y seca, clasificados como: Grupo 1 (E-cariofileno + germacreno D); Grupo 2 (germacreno D + E-cariofileno); Grupo 3 (α-humuleno + E-cariofileno); y Grupo 4 (α-curcumeno + E-cariofileno). Todos los aceites esenciales de L. camara, que representan los cuatro grupos químicos, inhibieron P. serpens con bajas concentraciones, considerando los siguientes valores de CI50:18,34 ± 6,60 µg / mL (LAC-018, grupo 1); 9,14 ± 3,87 µg / ml (LAC-027, grupo 2); 14,56 ± 3,40 µg / ml (LAC-037, grupo 3); y 14,97 ± 2,68 µg / ml (LAC-019, grupo 4).


Assuntos
Estações do Ano , Óleos Voláteis/química , Verbenaceae/química , Antiprotozoários/química , Terpenos/análise , Óleos Voláteis/farmacologia , Trypanosomatina/efeitos dos fármacos , Estação Seca , Estação Chuvosa , Antiprotozoários/farmacologia
4.
Mar Drugs ; 18(4)2020 Mar 31.
Artigo em Inglês | MEDLINE | ID: mdl-32244488

RESUMO

Neglected Tropical Diseases (NTD) represent a serious threat to humans, especially for those living in poor or developing countries. Almost one-sixth of the world population is at risk of suffering from these diseases and many thousands die because of NTDs, to which we should add the sanitary, labor and social issues that hinder the economic development of these countries. Protozoan-borne diseases are responsible for more than one million deaths every year. Visceral leishmaniasis, Chagas disease or sleeping sickness are among the most lethal NTDs. Despite not being considered an NTD by the World Health Organization (WHO), malaria must be added to this sinister group. Malaria, caused by the apicomplexan parasite Plasmodium falciparum, is responsible for thousands of deaths each year. The treatment of this disease has been losing effectiveness year after year. Many of the medicines currently in use are obsolete due to their gradual loss of efficacy, their intrinsic toxicity and the emergence of drug resistance or a lack of adherence to treatment. Therefore, there is an urgent and global need for new drugs. Despite this, the scant interest shown by most of the stakeholders involved in the pharmaceutical industry makes our present therapeutic arsenal scarce, and until recently, the search for new drugs has not been seriously addressed. The sources of new drugs for these and other pathologies include natural products, synthetic molecules or repurposing drugs. The most frequent sources of natural products are microorganisms, e.g., bacteria, fungi, yeasts, algae and plants, which are able to synthesize many drugs that are currently in use (e.g. antimicrobials, antitumor, immunosuppressants, etc.). The marine environment is another well-established source of bioactive natural products, with recent applications against parasites, bacteria and other pathogens which affect humans and animals. Drug discovery techniques have rapidly advanced since the beginning of the millennium. The combination of novel techniques that include the genetic modification of pathogens, bioimaging and robotics has given rise to the standardization of High-Performance Screening platforms in the discovery of drugs. These advancements have accelerated the discovery of new chemical entities with antiparasitic effects. This review presents critical updates regarding the use of High-Throughput Screening (HTS) in the discovery of drugs for NTDs transmitted by protozoa, including malaria, and its application in the discovery of new drugs of marine origin.


Assuntos
Antiprotozoários/farmacologia , Organismos Aquáticos/química , Produtos Biológicos/farmacologia , Infecções por Euglenozoa/tratamento farmacológico , Malária Falciparum/tratamento farmacológico , Doenças Negligenciadas/tratamento farmacológico , Animais , Antiprotozoários/uso terapêutico , Produtos Biológicos/uso terapêutico , Descoberta de Drogas , Resistência a Medicamentos , Infecções por Euglenozoa/parasitologia , Ensaios de Triagem em Larga Escala , Humanos , Malária Falciparum/parasitologia , Doenças Negligenciadas/parasitologia , Plasmodium falciparum/efeitos dos fármacos , Plasmodium malariae/efeitos dos fármacos , Plasmodium malariae/patogenicidade , Trypanosomatina/efeitos dos fármacos
5.
Front Biosci (Landmark Ed) ; 23(5): 954-966, 2018 01 01.
Artigo em Inglês | MEDLINE | ID: mdl-28930584

RESUMO

The trypanosomatid-induced diseases are considered as neglected, because the countries where they kill people are not important markets for western big pharmaceutical companies. However, recently some effort has been made to translate the use of already known drugs to neglected infectious disease. Although many metals are essential to life, many disorders affecting metal homeostasis and bioavailability are responsible for several human diseases. Metals can be toxic even at very low concentrations and semimetals are classified as toxic and dangerous for the environment. However, metal- and metalloid-based therapeutic drugs have existed for centuries. Some of them, as antimony and arsenic compounds, are still the first line drugs used for the treatment of leishmaniasis and trypanosomiases in developing countries. Other metal complexes (as those of Ag, Pt, Pd and Au), already present in the market for cancer therapies or to cure bacterial infection or for anti-inflammatory treatments, have been proposed also against the vector-borne infections caused by trypanosomatids. The use of novel approaches based on nanotechnologies, allowing selective targeting, may represent a promising strategy to decrease the toxicity of these drugs.


Assuntos
Complexos de Coordenação/farmacologia , Leishmaniose/tratamento farmacológico , Metais/química , Tripanossomicidas/farmacologia , Trypanosomatina/efeitos dos fármacos , Tripanossomíase/tratamento farmacológico , Animais , Complexos de Coordenação/química , Interações Hospedeiro-Parasita/efeitos dos fármacos , Humanos , Leishmaniose/parasitologia , Resultado do Tratamento , Tripanossomicidas/química , Trypanosomatina/fisiologia , Tripanossomíase/parasitologia
6.
Parasitology ; 145(3): 355-370, 2018 03.
Artigo em Inglês | MEDLINE | ID: mdl-29039273

RESUMO

The species Phytomonas serpens is known to express some molecules displaying similarity to those described in trypanosomatids pathogenic to humans, such as peptidases from Trypanosoma cruzi (cruzipain) and Leishmania spp. (gp63). In this work, a population of P. serpens resistant to the calpain inhibitor MDL28170 at 70 µ m (MDLR population) was selected by culturing promastigotes in increasing concentrations of the drug. The only relevant ultrastructural difference between wild-type (WT) and MDLR promastigotes was the presence of microvesicles within the flagellar pocket of the latter. MDLR population also showed an increased reactivity to anti-cruzipain antibody as well as a higher papain-like proteolytic activity, while the expression of calpain-like molecules cross-reactive to anti-Dm-calpain (from Drosophila melanogaster) antibody and calcium-dependent cysteine peptidase activity were decreased. Gp63-like molecules also presented a diminished expression in MDLR population, which is probably correlated to the reduction in the parasite adhesion to the salivary glands of the insect vector Oncopeltus fasciatus. A lower accumulation of Rhodamine 123 was detected in MDLR cells when compared with the WT population, a phenotype that was reversed when MDLR cells were treated with cyclosporin A and verapamil. Collectively, our results may help in the understanding of the roles of calpain inhibitors in trypanosomatids.


Assuntos
Inibidores de Cisteína Proteinase/farmacologia , Dipeptídeos/farmacologia , Proteínas de Membrana Transportadoras/efeitos dos fármacos , Peptídeo Hidrolases/efeitos dos fármacos , Trypanosomatina/efeitos dos fármacos , Calpaína/antagonistas & inibidores , Calpaína/química , Calpaína/efeitos dos fármacos , Calpaína/genética , Cisteína Endopeptidases/imunologia , Resistência a Medicamentos , Glicoproteínas/farmacologia , Leishmania/química , Leishmania/fisiologia , Proteínas de Membrana Transportadoras/genética , Peptídeo Hidrolases/genética , Proteínas de Protozoários/imunologia , Trypanosoma cruzi/química , Trypanosoma cruzi/fisiologia , Trypanosomatina/genética
7.
Free Radic Biol Med ; 113: 255-266, 2017 12.
Artigo em Inglês | MEDLINE | ID: mdl-28993269

RESUMO

Reactive oxygen species (ROS) are toxic molecules involved in several biological processes such as cellular signaling, proliferation, differentiation and cell death. Adaptations to oxidative environments are crucial for the success of the colonization of insects by protozoa. Strigomonas culicis is a monoxenic trypanosomatid found in the midgut of mosquitoes and presenting a life cycle restricted to the epimastigote form. Among S. culicis peculiarities, there is an endosymbiotic bacterium in the cytoplasm, which completes essential biosynthetic routes of the host cell and may represent an intermediary evolutive step in organelle origin, thus constituting an interesting model for evolutive researches. In this work, we induced ROS resistance in wild type S. culicis epimastigotes by the incubation with increasing concentrations of hydrogen peroxide (H2O2), and compared the oxidative and energetic metabolisms among wild type, wild type-H2O2 resistant and aposymbiotic strains. Resistant protozoa were less sensitive to the oxidative challenge and more dependent on oxidative phosphorylation, which was demonstrated by higher oxygen consumption and mitochondrial membrane potential, increased activity of complexes II-III and IV, increased complex II gene expression and higher ATP production. Furthermore, the wild type-H2O2 resistant strain produced reduced ROS levels and showed lower lipid peroxidation, as well as an increase in gene expression of antioxidant enzymes and thiol-dependent peroxidase activity. On the other hand, the aposymbiotic strain showed impaired mitochondrial function, higher H2O2 production and deficient antioxidant response. The induction of H2O2 resistance also led to a remarkable increase in Aedes aegypti midgut binding in vitro and colonization in vivo, indicating that both the pro-oxidant environment in the mosquito gut and the oxidative stress susceptibility regulate S. culicis population in invertebrates.


Assuntos
Aedes/parasitologia , Complexo de Proteínas da Cadeia de Transporte de Elétrons/genética , Metabolismo Energético/genética , Interações Hospedeiro-Parasita , Peróxido de Hidrogênio/farmacologia , Proteínas de Protozoários/genética , Trypanosomatina/metabolismo , Trifosfato de Adenosina/biossíntese , Animais , Antioxidantes/metabolismo , Betaproteobacteria/metabolismo , Evolução Biológica , Resistência a Medicamentos , Complexo de Proteínas da Cadeia de Transporte de Elétrons/metabolismo , Trato Gastrointestinal/parasitologia , Regulação da Expressão Gênica , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/genética , Mitocôndrias/metabolismo , Oxirredução , Estresse Oxidativo , Proteínas de Protozoários/metabolismo , Transdução de Sinais , Simbiose/fisiologia , Trypanosomatina/efeitos dos fármacos , Trypanosomatina/genética , Trypanosomatina/microbiologia
8.
Eur J Med Chem ; 126: 1129-1135, 2017 Jan 27.
Artigo em Inglês | MEDLINE | ID: mdl-28064141

RESUMO

Chalcones display a broad spectrum of pharmacological activities. Herein, a series of 2'-hydroxy methoxylated chalcones was synthesized and evaluated towards Trypanosoma brucei, Trypanosoma cruzi and Leishmania infantum. Among the synthesized library, compounds 1, 3, 4, 7 and 8 were the most potent and selective anti-T. brucei compounds (EC50 = 1.3-4.2 µM, selectivity index >10-fold). Compound 4 showed the best early-tox and antiparasitic profile. The pharmacokinetic studies of compound 4 in BALB/c mice using hydroxypropil-ß-cyclodextrins formulation showed a 7.5 times increase in oral bioavailability.


Assuntos
Antiparasitários/química , Antiparasitários/farmacologia , Chalconas/química , Chalconas/farmacologia , Animais , Antiparasitários/farmacocinética , Antiparasitários/toxicidade , Linhagem Celular Tumoral , Chalconas/farmacocinética , Chalconas/toxicidade , Ciclodextrinas/química , Portadores de Fármacos/química , Camundongos , Solubilidade , Trypanosomatina/efeitos dos fármacos
9.
Biochim Biophys Acta ; 1857(8): 1247-1257, 2016 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-26951942

RESUMO

In this review, we summarize our knowledge about mitochondrial potassium channels, with a special focus on unanswered questions in this field. The following potassium channels have been well described in the inner mitochondrial membrane: ATP-regulated potassium channel, Ca(2+)-activated potassium channel, the voltage-gated Kv1.3 potassium channel, and the two-pore domain TASK-3 potassium channel. The primary functional roles of these channels include regulation of mitochondrial respiration and the alteration of membrane potential. Additionally, they modulate the mitochondrial matrix volume and the synthesis of reactive oxygen species by mitochondria. Mitochondrial potassium channels are believed to contribute to cytoprotection and cell death. In this paper, we discuss fundamental issues concerning mitochondrial potassium channels: their molecular identity, channel pharmacology and functional properties. Attention will be given to the current problems present in our understanding of the nature of mitochondrial potassium channels. This article is part of a Special Issue entitled 'EBEC 2016: 19th European Bioenergetics Conference, Riva del Garda, Italy, July 2-6, 2016', edited by Prof. Paolo Bernardi.


Assuntos
Mitocôndrias/metabolismo , Canais de Potássio Cálcio-Ativados/metabolismo , Canais de Potássio Corretores do Fluxo de Internalização/metabolismo , Canais de Potássio de Domínios Poros em Tandem/metabolismo , Canais de Potássio de Abertura Dependente da Tensão da Membrana/metabolismo , Animais , Células Epiteliais/citologia , Células Epiteliais/efeitos dos fármacos , Células Epiteliais/metabolismo , Expressão Gênica , Humanos , Transporte de Íons , Mitocôndrias/efeitos dos fármacos , Miócitos Cardíacos/citologia , Miócitos Cardíacos/efeitos dos fármacos , Miócitos Cardíacos/metabolismo , Neurônios/citologia , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Especificidade de Órgãos , Plantas/efeitos dos fármacos , Plantas/metabolismo , Bloqueadores dos Canais de Potássio/farmacologia , Canais de Potássio Cálcio-Ativados/antagonistas & inibidores , Canais de Potássio Cálcio-Ativados/genética , Canais de Potássio Corretores do Fluxo de Internalização/antagonistas & inibidores , Canais de Potássio Corretores do Fluxo de Internalização/genética , Canais de Potássio de Domínios Poros em Tandem/antagonistas & inibidores , Canais de Potássio de Domínios Poros em Tandem/genética , Canais de Potássio de Abertura Dependente da Tensão da Membrana/antagonistas & inibidores , Canais de Potássio de Abertura Dependente da Tensão da Membrana/genética , Saccharomyces cerevisiae/efeitos dos fármacos , Saccharomyces cerevisiae/metabolismo , Linfócitos T/citologia , Linfócitos T/efeitos dos fármacos , Linfócitos T/metabolismo , Trypanosomatina/efeitos dos fármacos , Trypanosomatina/metabolismo
10.
Trends Parasitol ; 31(8): 373-9, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-26004537

RESUMO

Despite recent research linking cAMP signalling to virulence in trypanosomatids and detailed studies of trypanosomatid adenylyl cyclases (ACs) and phosphodiesterases (PDEs) since their discoveries 40 years ago, downstream components of the pathway and their biological functions have remained remarkably elusive. However, in recent years, significant discoveries have been made: a role for parasite ACs has been proposed in cytokinesis, evasion of the host immune response, and social motility. cAMP phosphodiesterases PDEB1 and PDEB2 were found to be essential for survival and virulence of Trypanosoma brucei and, in Trypanosoma cruzi, PDEC2 was shown to be required for normal osmoregulation. As we discuss here, these breakthroughs have led to an ongoing surge in the development of PDE inhibitors as lead compounds for trypanocidal drugs.


Assuntos
AMP Cíclico/metabolismo , Transdução de Sinais , Trypanosomatina/fisiologia , Trypanosomatina/patogenicidade , Adenilil Ciclases/metabolismo , Descoberta de Drogas , Infecções por Euglenozoa/parasitologia , Interações Hospedeiro-Parasita , Humanos , Inibidores de Fosfodiesterase/farmacologia , Diester Fosfórico Hidrolases/metabolismo , Tripanossomicidas/farmacologia , Trypanosomatina/efeitos dos fármacos , Trypanosomatina/enzimologia
11.
Curr Med Chem ; 22(18): 2186-98, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25787966

RESUMO

Sterols play an essential role in the physiology of eukaryotic cells; they play a pivotal role in the normal structure and function of cell membranes and also act as precursors for the synthesis of several different molecules like steroid hormones. Trypanosomatids and fungi have an essential requirement of ergosterol and other 24-alkyl sterols, which are absent in mammalian cells, for their survival and growth. At least 20 metabolic steps are necessary to synthesize sterols as cholesterol and ergosterol with the involvement of different specific enzymes. Some enzymes have been studied in detail in order to find new inhibitors that are able to abolish the parasite growth in vitro; besides, they also promote the curative efficacy in murine models of infection, thus opening new possibilities to introduce new drugs for the treatment of leishmaniasis and Chagas' disease. Sterols biosynthesis inhibitors (SBIs) can potentially be used as a chemotherapeutic agent against trypanosomatids. Actually, there are several drugs that interfere with the SB pathway, and some of them are already in clinical trials, such as posaconazole, and a new pro-drug, the ravuconazole. Furthermore, new approaches are being used, such as the combination of drugs, to reduce the resistance and minimize toxic effects. In this review, we discuss the main steps of the SB pathway, showing each enzyme involved in the steps, as well as the antiproliferative, physiological, biochemical, and ultrastructural effects of the several known inhibitors.


Assuntos
Antineoplásicos/farmacologia , Antiprotozoários/farmacologia , Esteróis/farmacologia , Trypanosomatina/efeitos dos fármacos , Antineoplásicos/química , Antineoplásicos/metabolismo , Antiprotozoários/química , Antiprotozoários/metabolismo , Relação Dose-Resposta a Droga , Humanos , Testes de Sensibilidade Parasitária , Esteróis/biossíntese , Esteróis/química , Trypanosomatina/citologia
12.
Exp Parasitol ; 130(1): 13-21, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22033075

RESUMO

Phytomonas serpens synthesizes metallo- and cysteine-proteases that are related to gp63 and cruzipain, respectively, two virulence factors produced by pathogenic trypanosomatids. Here, we described the cellular distribution of gp63- and cruzipain-like molecules in P. serpens through immunocytochemistry and confocal fluorescence microscopy. Both proteases were detected in distinct cellular compartments, presenting co-localization in membrane domains and intracellular regions. Subsequently, we showed that exogenous proteins modulated the production of both protease classes, but in different ways. Regarding the metalloprotease, only fetal bovine serum (FBS) influenced the gp63 expression, reducing its surface exposition (≈30%). Conversely, the cruzipain-like molecule was differentially modulated according to the proteins: human and bovine albumins reduced its expression around 50% and 35%, respectively; mucin and FBS did not alter its production, while IgG and hemoglobin drastically enhanced its surface exposition around 7- and 11-fold, respectively. Additionally, hemoglobin induced an augmentation in the cell-associated cruzipain-like activity in a dose-dependent manner. A twofold increase of the secreted cruzipain-like protein was detected after parasite incubation with 1% hemoglobin compared to the parasites incubated in PBS-glucose. The results showed the ability of P. serpens in modulating the expression and the activity of proteolytic enzymes after exposition to exogenous proteins, with emphasis in its cruzipain-like molecules.


Assuntos
Cisteína Endopeptidases/biossíntese , Hemoglobinas/farmacologia , Imunoglobulina G/farmacologia , Metaloproteases/biossíntese , Albumina Sérica/farmacologia , Trypanosomatina/enzimologia , Animais , Bovinos , Relação Dose-Resposta a Droga , Humanos , Imuno-Histoquímica , Solanum lycopersicum/parasitologia , Microscopia Confocal , Mucinas/farmacologia , Proteínas de Protozoários , Soroalbumina Bovina/farmacologia , Trypanosomatina/efeitos dos fármacos
13.
Curr Med Chem ; 18(32): 5003-10, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-22050748

RESUMO

Aptamers are single-stranded oligonucleotides (ssDNA or RNA) selected from combinatorial libraries by an in vitro process and possess a specific three-dimensional structure depending on its sequence. These molecules are able to recognize and, eventually, alter the activity of their targets by binding directly in a similar way to antibodies. Over the last years, aptamer technology has been used in a wide range of diagnostic and therapeutic applications and, concretely, several strategies are currently being explored using aptamers against Plasmodium and trypanosomatid proteins associated with parasitic diseases which affect hundreds of millions people. One approach tries to block the interaction between the parasite and the host using aptamers targeting host-cell matrix receptors. A second strategy consists in attack the parasite intracellularly targeting heme group or interfering in the intracellular RNA transport. In another strategy, aptamers targeting invariant polypeptides could be used as a specific drug delivery system into the parasite. Finally, aptamers addressed to re-direct the immune response of the infected host are being studied. Other potential use of the aptamers is as biorecognition element in diagnostic systems for parasitic diseases. In this paper, we briefly review how aptamers against Plasmodium and trypanosomatids are discovered, with a focus on recent advances that improve the aptamers properties as a real tool for parasite fighting.


Assuntos
Aptâmeros de Nucleotídeos/uso terapêutico , Malária/diagnóstico , Malária/terapia , Plasmodium/efeitos dos fármacos , Trypanosomatina/efeitos dos fármacos , Animais , Antimaláricos/isolamento & purificação , Aptâmeros de Nucleotídeos/genética , Humanos , Malária/parasitologia , Plasmodium/genética , Trypanosomatina/genética
14.
Curr Drug Targets ; 11(12): 1614-30, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20735352

RESUMO

The diseases caused by the trypanosomatid parasites Trypanosoma brucei, Trypanosoma cruzi and Leishmania are widely distributed throughout the world. Because of the toxic side-effects and the economically unviable cost of the currently used pharmaceutical treatments, the search for new drug targets continues. Since the antioxidant metabolism in these parasites relies on trypanothione [T(SH)(2)], a functional analog of glutathione, most of the pathway enzymes involved in its synthesis, utilization and reduction have been proposed as drug targets for therapeutic intervention. In the present review, the antioxidant metabolism and the phenotypic effects of inhibiting by genetic (RNA interference, knock-out) or chemical approaches, the T(SH)(2) and polyamine pathway enzymes in the parasites are analyzed. Although the genetic strategies are helpful in identifying essential genes for parasite survival/infectivity, they are less useful for drug-target validation. The effectiveness of targeting each pathway enzyme was evaluated by considering (i) the enzyme kinetic properties and antioxidant metabolite concentrations and (ii) the current knowledge and experimental approaches to the study of the control of fluxes and intermediary concentrations in metabolic pathways. The metabolic control analysis indicates that highly potent and specific inhibitors have to be designed for trypanothione reductase and the peroxide detoxification system, and hence other enzymes emerge (γ-glutamylcysteine synthetase, trypanothione synthetase, ornithine decarboxylase, S-adenosylmethionine decarboxylase and polyamine transporters) as alternative more suitable and effective drug targets in the antioxidant metabolism of trypanosomatids.


Assuntos
Desenho de Fármacos , Inibidores Enzimáticos/farmacologia , Glutationa/análogos & derivados , Espermidina/análogos & derivados , Tripanossomicidas/farmacologia , Trypanosomatina/efeitos dos fármacos , Trypanosomatina/metabolismo , Antimetabólitos/efeitos adversos , Antimetabólitos/farmacologia , Antimetabólitos/uso terapêutico , Antioxidantes/metabolismo , Inibidores Enzimáticos/efeitos adversos , Inibidores Enzimáticos/metabolismo , Infecções por Euglenozoa/tratamento farmacológico , Glutationa/metabolismo , Humanos , Terapia de Alvo Molecular , NADH NADPH Oxirredutases/antagonistas & inibidores , NADH NADPH Oxirredutases/fisiologia , Peróxidos/metabolismo , Proteínas de Protozoários/antagonistas & inibidores , Proteínas de Protozoários/fisiologia , Espermidina/metabolismo , Tripanossomicidas/efeitos adversos , Tripanossomicidas/uso terapêutico , Trypanosomatina/genética
15.
Mini Rev Med Chem ; 9(6): 674-86, 2009 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19519493

RESUMO

Trypanosomatid (order Kinetoplastida)-borne neglected tropical diseases - African and American trypanosomiasis and leishmaniasis - are amongst the most devastating health threats of underdeveloped, developing and poor countries. Climatic changes due to global warming, tourism exchange and increasing migratory fluxes are re-distributing the endemic subtropical location of these diseases to a new scenario with a rising presence in developed countries during the last decades. In addition, the proved opportunistic transmission of these diseases through contaminated syringes shared by drug users, in combination with immunosuppression processes linked to HIV infections and the poor response to the typical treatments, point to AIDS patients as a sensitive sub-population prone to suffer from these diseases. DNA topoisomerases are the "molecular engineers" that unravel the DNA during replication and transcription. The mechanism of DNA unwinding includes the scission of a single DNA strand - type I topoisomerases - or both DNA strands - type II topoisomerases - establishing transient covalent bonds with the scissile end. Camptothecin and etoposide - two natural drugs whose semi-synthetic derivatives are currently used in cancer chemotherapy - target types I and II DNA-topoisomerases respectively, stabilizing ternary topoisomerase-DNA-drug covalent complexes, which irreversibly poison the enzymes. Several differences between parasite and host DNA topoisomerases have pointed to these enzymes as potential drug targets in Trypanosomatids. The unusual localization inside the mitochondria-like organellum - the kinetoplast - linked to mini and maxicircles, as well as the uncommon heterodimeric structure of the DNA topoisomerase IB subfamily, make these proteins unquestionable targets for drug intervention against trypanosomatids.


Assuntos
Inibidores Enzimáticos/farmacologia , Inibidores Enzimáticos/uso terapêutico , Infecções por Protozoários/tratamento farmacológico , Infecções por Protozoários/parasitologia , Inibidores da Topoisomerase I , Trypanosomatina/efeitos dos fármacos , Trypanosomatina/enzimologia , Animais , DNA Topoisomerases Tipo I/metabolismo , Humanos
16.
Parasitology ; 136(1): 35-44, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19126268

RESUMO

Trypanosomatid protozoa include heteroxenic species some of them pathogenic for men, animals and plants. Parasite membrane contains ecto-enzymes whose active sites face the external medium rather than the cytoplasm. Herpetomonas sp. displayed a Mg2+-dependent ecto-ATPase activity, a Mg-independent ecto-ADPase and an ecto-phosphatase activity. Both, the ecto-ADPase and phosphatase activities were insensitive to CrATP (chromium(III) adenosine 5'-triphosphate complex). Ecto-ATPase activity was reversibly inhibited. At 2 mm ATP the apparent Ki was 4 x 7+/-1 x 0 microm but a fraction of about 40-50% was insensitive to CrATP. Remarkably, at low substrate concentration (0 x 2 mm) more than 90% of the ecto-ATPase was inhibited with Ki=0 x 33+/-0 x 10 microm. These parameter dependences are interpreted as the presence of 2 ecto-ATPases activities, one of them with high ATP apparent affinity and sensitivity to CrATP. DIDS (4,4 diisothiocyanatostilbene 2,2' disulfonic acid), suramin and ADP were also effective as inhibitors. Only ADP presented no additive inhibition with CrATP. The pattern of partial inhibition by CrATP was also observed for the ecto-ATPase activities of Leishmania amazonensis, Trypanosoma cruzi and Trypanosoma rangeli. CrATP emerges as a new inhibitor of ecto-ATPases and as a tool for a better understanding of properties and role of ecto-ATPases in the biology of parasites.


Assuntos
Adenosina Trifosfatases/metabolismo , Trifosfato de Adenosina/farmacologia , Inibidores Enzimáticos/farmacologia , Trypanosomatina/efeitos dos fármacos , Trypanosomatina/enzimologia , Ácido 4,4'-Di-Isotiocianoestilbeno-2,2'-Dissulfônico/farmacologia , Difosfato de Adenosina/farmacologia , Adenosina Trifosfatases/antagonistas & inibidores , Animais , Suramina/farmacologia , Fatores de Tempo
17.
Microbes Infect ; 10(6): 642-9, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18457978

RESUMO

Monoxenic trypanosomatids, which usually are non-pathogenic in humans, have been detected in AIDS patients, but the mechanisms underlying the establishment of these protozoa in HIV-1-infected individuals are poorly understood. Here we addressed the role of HIV-1 and the HIV-1 Tat protein in the replication of the monoxenic trypanosomatid Blastocrithidia culicis in HIV-1-infected primary human macrophages. We found that HIV-1 and B. culicis replication augmented almost three times in co-infected macrophages, and that Tat antiserum significantly reduced the exacerbated protozoan growth. Exposure of B. culicis only infected macrophages to Tat protein also resulted in enhanced protozoan proliferation, reaching a twofold increase at 100 ng/mL. Electron microscopy analysis revealed that B. culicis and HIV-1 co-habit the same cells, and showed protozoan dividing forms inside macrophages. Protozoan replication diminished when B. culicis only infected macrophages were treated with Tat protein in the presence of anti-TGF-beta1 antibodies, suggesting a participation of this cytokine in the augmentation of protozoan multiplication. In fact, exogenous TGF-beta1 promoted the trypanosomatid replication in macrophages. Overall, our results suggest that HIV-1 infection deactivates the macrophage microbicidal activity, permitting the survival and multiplication of an otherwise non-pathogenic protozoan in these cells, a process partially mediated by Tat protein, via TGF-beta1 secretion.


Assuntos
Infecções por HIV/patologia , HIV-1/química , Macrófagos/efeitos dos fármacos , Fator de Crescimento Transformador beta1/fisiologia , Trypanosomatina/efeitos dos fármacos , Produtos do Gene tat do Vírus da Imunodeficiência Humana/farmacologia , Animais , Humanos , Macrófagos/parasitologia , Trypanosomatina/fisiologia , Produtos do Gene tat do Vírus da Imunodeficiência Humana/imunologia
18.
Adv Exp Med Biol ; 625: 33-47, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18365657

RESUMO

Kinetoplastid parasites are responsible for the potentially fatal diseases leishmaniasis, African sleeping sickness and Chagas disease. The current treatments for these diseases are far from ideal and new compounds are needed as antiparasitic drug candidates. Tubulin is the accepted target for treatments against cancer and helminths, suggesting that kinetoplastid tubulin is also a suitable target for antiprotozoal compounds. Selective lead compounds against kinetoplastid tubulin have been identified that could represent a starting point for the development of new drug candidates against these parasites.


Assuntos
Tripanossomicidas/farmacologia , Trypanosomatina/efeitos dos fármacos , Tubulina (Proteína)/metabolismo , Animais , DNA de Cinetoplasto/química , DNA de Cinetoplasto/efeitos dos fármacos , DNA de Cinetoplasto/metabolismo , Tubulina (Proteína)/química , Tubulina (Proteína)/efeitos dos fármacos
19.
Mem. Inst. Oswaldo Cruz ; 102(5): 601-604, Aug. 2007. tab, graf
Artigo em Inglês | LILACS | ID: lil-458631

RESUMO

We investigated the effect of two modulators of protein kinase C, sphingosine and phorbol-12-myristate-13-acetate (PMA), on the growth and dimethylsulfoxide (DMSO)-induced differentiation in Herpetomonas samuelpessoai. Sphingosine did not stimulate the transformation of undifferentiated-promastigotes in differentiated-paramastigotes. PMA alone or in association with DMSO increased the number of paramastigotes in comparison to control cells. DMSO inhibited the parasite growth (35 percent) and several unusual morphological features resembling aberrant cell division were observed. Sphingosine did not significantly reduce the growth in contrast to PMA. Collectively, our results demonstrated that the reduction of the proliferation translates in an increase of the differentiation rate in the insect trypanosomatid H. samuelpessoai.


Assuntos
Animais , Dimetil Sulfóxido/farmacologia , Proteína Quinase C/efeitos dos fármacos , Esfingosina/farmacologia , Acetato de Tetradecanoilforbol/farmacologia , Trypanosomatina/efeitos dos fármacos , Diferenciação Celular/efeitos dos fármacos , Ativação Enzimática/efeitos dos fármacos , Trypanosomatina/enzimologia , Trypanosomatina/crescimento & desenvolvimento
20.
Int J Parasitol ; 36(4): 415-22, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16500661

RESUMO

The cell-associated and extracellular peptidases of Herpetomonas megaseliae grown in brain-heart infusion and in modified Roitman's complex media were analyzed by measuring peptidase activity on gelatin, casein and hemoglobin in zymograms. Casein was the best proteinaceous substrate for the peptidase detection on both growth conditions. However, no proteolytic activity was detected when hemoglobin was used. Our results showed that cellular cysteine peptidase (115-100, 40 and 35 kDa) and metallopeptidase (70 and 60 kDa) activities were detected on both media in casein and gelatin zymograms. Additionally, the use of casein in the gel revealed a distinct acidic metallopeptidase of 50 kDa when the parasite was cultured in the modified Roitman's complex medium. Irrespective of the culture medium composition, H. megaseliae released metallopeptidases exclusively in the extracellular environment. The presence of gp63-like molecules on the H. megaseliae surface was shown by flow cytometry using anti-gp63 antibody raised against recombinant gp63 from Leishmania mexicana. The pre-treatment of parasites with phospholipase C reduced the number of gp63-positive cells, suggesting that these molecules were glycosylphosphatidylinositol-anchored to the surface. Additionally, the supernatant obtained from phospholipase C-treated cells and probed with anti-cross-reacting determinant confirmed that at least a 52 kDa gp63-like molecule is glycosylphosphatidylinositol-anchored. Furthermore, we assessed a possible function for the gp63-like molecules in H. megaseliae on the interaction with explanted guts of its original host, Megaselia scalaris, and with an experimental model employing Aedes aegypti. Parasites pre-treated with either anti-gp63 antibody or phospholipase C showed a significant reduction in the adhesion to M. scalaris and A. aegypti guts. Similarly, the pre-treatment of the explanted guts with purified gp63 diminished the interaction process. Collectively, these results corroborate the ubiquitous existence of gp63 homologues in insect trypanosomatids and the potential adhesion of these molecules to invertebrate host tissues.


Assuntos
Metaloendopeptidases/fisiologia , Peptídeo Hidrolases/fisiologia , Trypanosomatina/fisiologia , Aedes/parasitologia , Animais , Adesão Celular/fisiologia , Meios de Cultura , Dípteros/parasitologia , Citometria de Fluxo/métodos , Interações Hospedeiro-Parasita , Insetos Vetores/parasitologia , Intestinos/parasitologia , Metaloendopeptidases/metabolismo , Peptídeo Hidrolases/metabolismo , Trypanosomatina/efeitos dos fármacos , Trypanosomatina/metabolismo , Fosfolipases Tipo C/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA